Alternative Data for Puma Biotechnology
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 10 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,859 | Sign up | Sign up | Sign up |
| X Followers | 93 | Sign up | Sign up | Sign up |
| X Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 19 | Sign up | Sign up | Sign up |
| Linkedin Employees | 248 | Sign up | Sign up | Sign up |
About Puma Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
| Price | $5.88 |
| Target Price | Sign up |
| Volume | 377,222 |
| Market Cap | $308M |
| Year Range | $3.07 - $7.68 |
| Dividend Yield | 0% |
| PE Ratio | 9.93 |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
 |
Earnings Scheduled For February 26, 2026February 25 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 54M | 12M | 42M | 8.8M | 13M | 0.210 |
| Q2 '25 | 52M | 12M | 40M | 5.9M | 11M | 0.150 |
| Q1 '25 | 46M | 11M | 35M | 3M | 8.2M | 0.100 |
| Q4 '24 | 59M | 14M | 45M | 19M | 18M | 0.430 |
| Q3 '24 | 81M | 29M | 51M | 20M | 27M | 0.410 |
Insider Transactions View All
| NOUGUES MAXIMO F filed to sell 193,284 shares at $5.9. January 8 '26 |
| HUNT DOUGLAS M filed to sell 155,907 shares at $5.9. January 8 '26 |
| AUERBACH ALAN H filed to sell 7,145,951 shares at $5.9. January 8 '26 |
| NOUGUES MAXIMO F filed to sell 199,689 shares at $5.8. January 8 '26 |
| HUNT DOUGLAS M filed to sell 160,921 shares at $5.8. January 8 '26 |
Similar companies
Read more about Puma Biotechnology (PBYI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Puma Biotechnology
The Market Cap of Puma Biotechnology is $308M.
As of today, Puma Biotechnology's PE (Price to Earnings) ratio is 9.93.
Currently, the price of one share of Puma Biotechnology stock is $5.88.
The PBYI stock price chart above provides a comprehensive visual representation of Puma Biotechnology's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Puma Biotechnology shares. Our platform offers an up-to-date PBYI stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Puma Biotechnology (PBYI) does not offer dividends to its shareholders. Investors interested in Puma Biotechnology should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Puma Biotechnology are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
